Your session is about to expire
← Back to Search
ICONIC-LEAD Trial Summary
This trial will study if a new drug is effective at treating moderate to severe plaque psoriasis.
- Plaque Psoriasis
ICONIC-LEAD Trial Eligibility Criteria
Inclusion CriteriaYou will be eligible if you check “Yes” for the criteria below
ICONIC-LEAD Trial Timeline
Study ObjectivesOutcome measures can provide a clearer picture of what you can expect from a treatment.
Awards & Highlights
ICONIC-LEAD Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
What is the current enrolment capacity for this investigation?
"This study requires 600 participants who meet its prerequisites to take part. Individuals can enrol through the Indiana Clinical Trial Center in Plainfield, IN or Dermatology and Advanced Aesthetics in Lake Charles, LA."
Are there copious facilities executing this research in North America?
"Indiana Clinical Trial Center in Plainfield, Dermatology and Advanced Aesthetics in Lake Charles, Michigan Center of Medical Research in Clarkston, and 6 other sites are providing this medical treatment."
Are individuals eligible to participate in this experimental research at the present time?
"According to clinicaltrials.gov, the search for participants is ongoing and has been since October 12th 2023 when it was posted; as of 18th October that date had not changed."
Has JNJ-77242113 been granted sanction by the FDA?
"Judging by the Phase 3 trial data, our experts at Power rate JNJ-77242113 as a 3 on the safety scale. This is because there exists supportive evidence of its efficacy and validated research that corroborates its security."
What is the intended outcome of this experiment?
"The purpose of the study, which will be observed from Baseline to Week 16 is to analyse how many participants achieved a Psoriasis Area and Severity Index (PASI) 90 Response at Week 16. Secondary assessments include tracking PASI 75 Responses (>=75% improvement in PASI from baseline) at Weeks 4 and 16, as well as evaluating patients' reactions to reaching a PASI 90 Response (>=90% improvement in PASI from baseline) at Week 8 or achieving a full-fledged remission with a score of 100 by Week 16. The comprehensive evaluation system for this trial - known as the"
Who else is applying?
What site did they apply to?
What portion of applicants met pre-screening criteria?
Why did patients apply to this trial?
Share this study with friends